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Bayesian regression models, which are more ﬂexible and are
simple to implement in freely available software. RESULTS:
Using health outcomes research examples for illustration in each
case, we describe common methodology issues arising from use
of these methods, such as when small numbers of trials are
analysed, when unequal trial sizes are included and when excess
variability between trials (or heterogeneity) is encountered.
CONCLUSIONS: For the methods considered, we offer possible
solutions, make recommendations for their use and point out sit-
uations in which caution should be exercised.
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OBJECTIVES: 1) To examine the percent difference between
average wholesale price (AWP) and wholesale acquisition cost
(WAC) for pharmaceuticals in the United States, accounting 
for patent status and manufacturer type, and 2) to evaluate the
relationship between brand manufacturers and relabelers.
METHODS: Data for this study came from the Master Drug
Data Base (MDDB), which is a proprietary drug ﬁle containing
pricing information for all prescription and non-prescription
products available in the US. The percent difference between
AWP and WAC for prescription pharmaceuticals was compared
on a variety of facets, including single source, type of manufac-
turer (original or repackager). The difference was expressed as a
percentage of AWP (a commonly used method for reimbursing
pharmacies in the US). We also compared the AWP among brand
name manufacturers and relabelers (who repackage brand name
pharmaceuticals produced by the original manufacturer).
RESULTS: A total of 23,607 unique drug products were included
in the analysis examining AWP and WAC. The mean percent dif-
ference for brand name pharmaceuticals was 0.23 + 0.11, as
compared to 0.44 + 0.26, p < 0.001. Brand name drugs that were
available from multiple companies had a mean difference of 0.25
+ 0.14, compared to 0.20 + 0.05 for single source products (p <
0.001). The median AWP for brand name manufacturers was
$3.04 per unit, compared to $3.11 per unit for relablers. CON-
CLUSION: This study documents the magnitude of well-known
differences between AWP and WAC for brand name and generic
products. Further, branded products produced by more than one
manufacturer will have larger differences between AWP and
WAC than single source products. The ﬁndings suggest the need
for analysts to critically evaluate the use of AWP for determin-
ing product costs in the US and substantial differences exist
between single source and multiple source products. A more
transparent and accurate pricing system is needed for economic
analyses in the US.
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OBJECTIVE: The Centers for Medicare and Medicaid Services
(CMS) assigns relative weights to procedures in the hospital out-
patient setting and may do so for pharmacy handling costs in
2006. This study examines the current approach to assignment
of relative weights for drug and biological administration codes
under the CMS Hospital Outpatient Prospective Payment System
(OPPS) and compares this approach to the resource-based level
of effort concept initially created for payment to physicians.
METHODS: Resource-based methods originally proposed for
the hospital OPPS and equivalent measurement methods in the
original Harvard RBRVS work were deconstructed and evalu-
ated. The MedPAC rationale for recommendation of relative
weights for payment of pharmacy handling costs and the pro-
posed weights were also examined and evaluated. RESULTS:
The evaluation sought indications of resource-based level of
effort applications in the OPPS and their comparability to the
original resource-based studies, especially in the area of intensity
measures. The underlying intent of the resource-based relative
value scale (RBRVS) was to create a hierarchy of resource-based
level of effort in physician service delivery. The concept of hos-
pital OPPS was also intended to reﬂect resource-based service
delivery. Procedures are assigned a relative weight, implying that
payment includes level of effort resources. Recommended 2006
handling costs for drugs are assigned ﬁve relative weights, each
compared to drawing up an injected drug for administration. We
postulate these relative weights contain insufﬁcient recognition
of the level of effort and resource consumption required, thus
distorting the concept’s initial intent. CONCLUSIONS: Many
researchers and policy makers assume that relative weights
equate to level of effort resource consumption in all instances.
We cannot ﬁnd this is so regarding the ﬁve levels of relative
weights recommended for OPPS pharmacy handling costs.
Because resource consumption is disproportionately greater than
relative weights assigned in many cases, the resulting payment
will be understated.
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OBJECTIVES: Pharmacoeconomic evaluation activities have
grown rapidly in recent years, but few economic evaluations
have focused on Medical Devices (MD). This study addresses the
barriers to conducting economic evaluations of MD, in compar-
ison with pharmacoeconomic evaluations, in order to develop a
framework for MD economic evaluation. METHODS: First, we
studied the differences between MD and drugs that possibly
impact on the completion of economic evaluations. Then, we
analysed items of the French Guidelines for Economic Evalua-
tions of Health Care Technologies developed by the “Collège des
Economistes de la Santé” [http://www.ces-asso.org/docs/France_
Guidelines_HE_Evaluation.PDF] that might be barriers to the
completion of MD economic evaluations, as compared to drugs,
and we developed suggestions to overcome these barriers.
RESULTS: In this abstract we present three of eight barriers to
performing economic evaluations of MD. The ﬁrst one relates to
the feasibility of clinical trials, e.g. inadequacy of “placebo” and
“double blinding” for MD testing and difﬁculty to include large
numbers of patients. We suggest performing comparative studies
for assessing clinical outcomes to be included in economic eval-
uations and to discuss potential bias. Secondly, MD is developed
by engineers who are used to assessing technical performance,
but not clinical and economic outcomes. We propose setting up
collaborations between engineers, health care professionals and
health economists from the very beginning of MD development.
Besides, MD effectiveness often depends on the operator (health
care professional or patient) and may change over time, when
the operator gains experience. Health economists must, there-
fore, analyse the transferability of economic evaluation results
from one setting to another and over time. CONCLUSION: We
recommend setting up multidisciplinary groups of engineers,
